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Objectives: The objectives of this study were to characterize ESBL-producing Enterobacteriaceae present in 24
neonatal units (NNUs) in eight networks participating in a multicentre probiotic study and to test the hypothesis
that specific strains would cluster within individual units and networks.
Methods: We performed analysis of stool samples for the presence of ESBL-producing Enterobacteriaceae
at 2 weeks post-natal age and 36 weeks post-menstrual age. ESBL-producing Enterobacteriaceae were
characterized and typed using molecular methods.
Results: ESBL-producing Enterobacteriaceae (n¼71) were isolated from 67/1229 (5.5%) infants from whom
we received a sample at either sampling time or both sampling times, and from infants in 18 (75%) of the 24
recruiting NNUs. Thirty-three Escherichia coli, 23 Klebsiella spp. and 6 Enterobacter spp. strains were character-
ized. ESBL-producing E. coli were all distinguishable within individual NNUs by antibiotic resistance genotype,
serogroup (O25b), phenotype, phylotype or ST. Ten of the 33 were ST131 and 9 of the 10 ST131 isolates were
ciprofloxacin resistant. Seven of the 10 ST131 isolates carried genes encoding CTX-M group 1 enzymes. ST131
isolates were isolated from centres within five of the eight NNU networks. Therewere clusters of indistinguishable
ESBL-producing Klebsiella and Enterobacter isolates associated with specific NNUs.
Conclusions: Strains of E. coli ST131were distributed across neonatal networks in the south of England. Therewas
no evidence of clustering of clonally related ESBL-producing E. coli strains, by contrast with Klebsiella spp. and
Enterobacter spp., which did cluster within units. The possibility that ESBL-producing E. coli strains are spread
by vertical transmission requires further investigation.
Introduction
ESBL-producing Enterobacteriaceae can cause outbreaks in
many contexts, including neonatal units (NNUs).1–3 The objec-
tives of this study were to identify the range of ESBL-producing
Enterobacteriaceae prevalent in NNUs participating in a multicen-
tre study in the south of England. There is evidence that virulent
clones of ESBL-producing Escherichia coli can be transmitted from
mothers to infants early in life,4,5 so a second objective was to
explore the relative importance of horizontal and vertical trans-
mission by determining the extent to which specific clones cluster
within NNUs or networks.
Methods
The PiPS study was a multicentre probiotic study (https://www.npeu.ox.ac.
uk/pips). Ethics approval for the PiPS study was given by the NRES
Committee South Central—Oxford A, Reference 09/H0604/30. A secondary
objective of the study was to determine rates of carriage of ESBL-
producing Enterobacteriaceae in the probiotic and placebo groups.
Infants were recruited between July 2010 and July 2013. Stool samples
were collected from infants at 2 weeks post-natal age and 36 weeks post-
menstrual age, and were transported to the microbiology laboratory at
Barts Health NHS Trust using the Thermacor transportation system
(Dyecor Ltd, Herefordshire, UK). Specimens were weighed and divided
into two equal parts. One half was stored at 2808C to allow additional
tests. The other half was diluted 1:10 in a cryopreservative broth (brain
heart infusion; Oxoid Ltd, Basingstoke, UK) containing 10% glycerol
(w/v), mixed by vortexing for 10 s and then placed in 1 mL aliquots into
sterile 1.5 mL Eppendorf tubes before freezing at 2808C.
Culture, identification and enumeration
of ESBL-producing Enterobacteriaceae
Vials of frozen samples in cryopreservativewere thawed at room tempera-
ture and serially diluted in brain heart infusion broth (Oxoid Ltd). Aliquots
(100 mL) of the neat sample and 1021, 1023 and 1025 dilutions were
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inoculated on to MacConkey and BrillianceTM ESBL agar (Oxoid Ltd).
Inoculated media were incubated at 378C for 24–36 h in air.
Bacterial colonies were enumerated and identified using standard
laboratory methods, including MALDI-TOF MS (Bruker UK Ltd). Gram-
negative bacilli that grew on MacConkey or Brilliance ESBL agars were
tested using the BSACdisc diffusionmethod and ESBL production was con-
firmed using cefotaxime/clavulanate and cefepime/clavulanate combined
disc tests (Total ESBL Confirm Kit, Rosco Diagnostica, Taastrup, Denmark).
When the same ESBL-producing species was isolated at both sampling
times, then only the 2 week post-natal age isolate was characterized.
Identification of resistance genes in ESBL isolates
DNA was released by inoculation of one colony into 100 mL of distilled
water and heating to 1008C for 10 min followed by centrifugation for
1 min. Multiplex PCR assays were used to detect the presence of genes
encoding major b-lactamase families (TEM, SHV, OXA-1/4/30/48, CTX-M
groups 1, 2 and 9, plasmidic AmpCs, VEB, PER, GES, IMP, VIM and
KPC-like),6 aminoglycoside-modifying enzymes (APH, ANT and AAC)7,8
and the aac(6′)-Ib-cr variant associated with fluoroquinolone resistance.9
All PCRs were carried out using Thermoprime ReddyMixTM PCR Master
Mix (Thermo Scientific, USA). Amplicons were visualized following electro-
phoresis on 1.5% agarose gels containing ethidium bromide at 100 V
for 40 min.
Molecular typing of E. coli
E. coli phylogroup was determined by PCR methods10 and allele-specific
PCRwas used to detect the 025b-ST131 subtype.11 Isolates were assigned
to major phylogroups A, B1, B2 or D based on differential amplification of
the ChuA, YjaA and TspE4.C2 DNA sequences. An internal control (TrpA
427 bp) was run with each sample for the 025b-ST131 allele PCR.
Sequence typing of E. coli
E. coli isolates belonging to major extra-intestinal pathogenic (ExPEC) STs
were identified using PCR and specific primers. The STs and product sizes
were: ST131, 310 bp; ST127, 404 bp; ST95, 200 bp; ST73, 490 bp; and ST69,
100 bp.12
Typing of Klebsiella spp. and Enterobacter spp.
Klebsiella pneumoniae were typed using variable-number tandem repeat
(VNTR) analysis13 using loci A, E, H, J, K and D, and three additional loci
(N1, N2 and N4). Enterobacter spp. and Klebsiella oxytoca were typed
using PFGE of XbaI-digested genomic DNA.13
Results
One thousand three hundred and fifteen infants were recruited to
the PiPS study from 24 NNUs in eight networks. Five were with-
drawn, leaving 1310. Stool samples were received at either time
from 1229 infants: from 1186 (94%) of the 1266 infants alive at
2 weeks post-natal age and 1043 (84%) of the 1235 alive at
36 weeks post-menstrual age. Fifteen percent of infants were
transferred to another NNU (usually within the same network)
on more than one occasion and the largest number of transfers
was 12 for a single infant. Transfers outside of networks were
either the result of overloaded capacity in a network or a require-
ment for a surgical or investigational procedure available in a
limited number of centres.
ESBL-producing Enterobacteriaceae were isolated from
67/1229 (5.5%) infants from whom samples were received at
either sampling time or both sampling times (39 infants from
whom 2 week samples were available and 39 infants from
whom the 36 week post-menstrual age sample was available;
for 11 of the infants samples were available from both sampling
times). Two species of ESBL-producing Enterobacteriaceae were
isolated from each of four infants at the same sampling time to
give a total of 71 isolates. Of these, 65 isolates were available
for characterization. These were 33 E. coli, 21 K. pneumoniae, 4
K. oxytoca, 6 Enterobacter cloacae and 1 Enterobacter aerogenes.
Only one colonized infant developed a bacteraemia with an
ESBL-producing K. pneumoniae.
The site distribution and characteristics of ESBL-producing
E. coli isolates are shown in Table 1. ESBL-producing E. coli were
isolated from infants in 18 (75%) of the 24 recruiting units. All
were distinguishable within NNUs by antibiotic resistance pheno-
type, genotype, serogroup (O25b), phylogroup or ST. Ten of 33
(30%) E. coli isolates were ST131; of these 10, 9 were ciprofloxacin
resistant and 7 produced CTX-M group 1 enzymes. ST131 isolates
were isolated from NNUs within five of the eight NNU networks
recruiting into the PiPS study. A single ST95 isolate was identified,
but the remaining 22 isolates did not belong to any of the three
other major ExPEC lineages sought (STs 69, 73, 127).
Klebsiella spp. and Enterobacter spp. typing results
ESBL-producing Klebsiella spp. were isolated from infants in eight
(33%) of the 24 recruiting centres. K. pneumoniae was the most
common species isolated, with three clusters of indistinguishable
isolates identified by VNTR analysis. The largest cluster, involving
isolates from five infants, was associated with one NNU (A5).
There was another cluster involving three infants at another
NNU (A1) and two infants at each of two NNUs who were found
to have strains from the widespread clonal complex ST15.14
Twelve of the 21 K. pneumoniae produced CTX-M group 1
enzymes. Two of the four K. oxytoca isolates were indistinguish-
able by PFGE typing and were associated with two infants in
one NNU.
The PFGE typing of ESBL-producing Enterobacter spp. showed
that five of the six E. cloacae isolates were indistinguishable by
PFGE. This strain has caused an ongoing outbreak in NNU G1
and two of the PiPS study infants colonized with this strain were
recruited at this centre. Both of these infants were re-located to
NNU A3 and subsequently a third infant in NNU A3 was found to
be colonized with the same strain. The other two infants with this
strain had been inpatients in NNU A1, which is in the same net-
work, or NNU D1, which is in the adjacent network to NNU A3.
None of the Enterobacteriaceae recovered was resistant
to carbapenems or carried KPC, IMP, VIM or OXA-48-like
carbapenemases.
Discussion
The primary and secondary outcomes of the PiPS study have
been published elsewhere, including the frequency of carriage
of ESBL-producing Enterobacteriaceae in the probiotic and
placebo groups.15 The overall prevalence of ESBL-producing
Enterobacteriaceae reported in this study (5.5%) is similar to the
figure reported from Germany (5.7%)16 and lower than that
reported in Italy (27.1%).17 We found no evidence to suggest
that there was transmission of ESBL-producing E. coli within
Millar et al.
2 of 4
 at Queen M
ary, University of London on January 12, 2016
http://jac.oxfordjournals.org/
D
ow
nloaded from
 
units. Ten of the 33 ESBL-producing E. coliwere ST131. There is evi-
dence of worldwide community spread of ST131.4 The H30 clade
is frequently ESBL producing and ciprofloxacin resistant.18 ST131
strains have been associatedwith transmissionwithin households
and hospitals, but seem to be transmitted more efficiently
amongst household as opposed to hospital contacts.19 All of
the ST131 E. coli strains in this study were phylogroup B2, which
has a propensity to carry a wide range of virulence genes.18
Even so, there were no ST131 strains associated with episodes
of late-onset infection in the PiPS study.
Carriage of ESBL-producing Enterobacteriaceae by the mother
may be an important risk factor for carriage by the infant.16 The
lack of clustering of individual strains of E. coli within individual
NNUs supports the plausibility of vertical acquisition. By contrast,
there was evidence that other ESBL-producing species (E. cloacae
and Klebsiella pneumoniae) were being transmitted within units
and networks, and across networks.
Conclusions
Despite being present, ST131 strains were not associated with
episodes of late-onset infection in this study. The diversity
of ESBL-producing E. coli strains observed is not consistent
with the view that acquisition is a consequence of horizontal
transmission. The role of vertical transmission requires further
investigation.20
Table 1. Characteristics of ESBL-producing E. coli
Infant Network Unit
Antibiogram Resistance determinants encoded Molecular typing
CIP/GEN/TOB/CHL b-lactamases
aminoglycoside-modifying
enzymes phylotype
ST
PCR
025b-ST131
allele
1 A A1 CIPR GENS SHV, CTX-M-1 Gp APH(3′)-Ia, AAC(6′)-Ib-cr B2 ST131 ST131-025b
2 A A2 CIPR TOBR GENS TEM, CTX-1 Gp ANT(3′′)-Ia, AAC(3′)-IIa NT ST131 NT
3 A A1 CIPR GENS TEM AAC(6′)-Ib-cr B2
4 A A1 CIPS GENS CTX-M-1 Gp B2
5 A A2 CIPS GENS TOBR CHLS CTX-M-1 Gp AAC(3′)-IIa B2
6 A A2 CIPS GENS CHLR CTX-M-1 Gp B2
7 A A3 CIPR TOBR GENS SHV, CTX-M-1 Gp ANT(3′′)-Ia B2
8 A A4 CIPR GENS CTX-M-1 Gp B2 ST131 ST131-025b
9 A A5 CIPR GENS CTX-M-2 Gp, CTX-M-9 Gp A ST131 NT
10 A A5 CIPS TOBR GENS CTX-M-1 Gp AAC(3′)-Ia, AAC(6′)-Ib B2
11 A A6 CIPS GENS TEM B2 ST95
12 B B1 CIPS GENS TEM, OXA-1/4/30 B2
13 C C1 CIPR TOBR GENR CTX-M-1 Gp AAC(3′)-IIa B2 ST131 ST131-025b
14 C C1 CIPR TOBR GENR TEM, OXA-1/4/30, CTX-M-1 Gp AAC(3′)-IIa B2 ST131 ST131-025b
15 C C1 CIPS TOBR GENR TEM AAC(6′)-Ib-cr, AAC(3′)-IIa D
16 C C1 CIPR GENS TEM B2
17 C C2 CIPR GENR TEM AAC(6′)-Ib-cr, AAC(3′)-IIa D
18 D D1 CIPR GENR TEM, CTX-M-2 Gp ANT(3′′)-Ia, AAC(3′)-IIa B2
19 D D2 CIPS GENS TEM AAC(6′)-Ib-cr B2
20 D D2 CIPR TOBR GENS SHV, CTX-M-1 Gp ANT(3′′)-Ia B2
21 D D2 CIPR GENS SHV, CTX-M-2 Gp, CTX-M-9 Gp A ST131 NT
22 D D1 CIPS GENS CTX-M-1 Gp ANT(3′′)-Ia A
23 D D1 CIPS GENS ANT(3′′)-Ia,
APH(3′)-Ia AAC(6′)-Ib-cr
B2
24 D D1 CIPS TOBR GENR CTX-M-1 Gp APH(3′)-Ia, AAC(6′)-Ib-cr,
AAC(3′)-IIa
D ST131 NT
25 E E1 CIPS GENR TEM ANT(3′′)-Ia, AAC(3′)-IIa NT
26 E E1 CIPR GENS SHV, CTX-M-1 Gp B2
27 E E2 CIPR GENS TEM, OXA-1/4/30, CTX-M-9 Gp AAC(6′)-Ib-cr NT ST131 NT
28 E E3 CIPS GENS TEM ANT(6′)-Ia B2
29 F F1 CIPS GENS CTX-M-1 Gp B2
30 G G1 CIPR GENS TEM, SHV, OXA-1/4/30, CTX-M-9Gp B2
31 G G1 CIPR GENS CTX-M-1 Gp AAC(3′)-Ia, AAC(3′)-IIa B2 ST131 ST131-025b
32 H H1 CIPS GENS TEM, CTX-1 Gp B2
33 H H2 CIPR GENS CTX-M-2 Gp, CTX-M-9 Gp NT
CIP, ciprofloxacin; TOB, tobramycin; GEN, gentamicin; CHL, chloramphenicol; R, resistant; S, susceptible; Gp, group; NT, not typeable.
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